Methimazole Inhibits the Expression of GFAP and the Migration of Astrocyte in Scratched Wound Model In Vitro [PDF]
Mediators of Inflammation, 2020 Astrocytes respond to central nervous system (CNS) insults with varieties of changes, such as cellular hypertrophy, migration, proliferation, scar formation, and upregulation of glial fibrillary acidic protein (GFAP) expression.
Lina Zhao, Xianyu Zhang, Chunhai Zhang
doaj +2 more sources
From antithyroid therapy to oral necrosis: oral manifestations of methimazole-induced agranulocytosis: a case report [PDF]
Journal of Medical Case ReportsBackground Methimazole is a widely used antithyroid medication with a well-documented risk of hematological adverse effects, particularly agranulocytosis.
Haitham Medhioub +5 more
doaj +2 more sources
Drug cross-reactivity between methimazole and propylthiouracil causing recurrent pancreatitis in thyroid storm [PDF]
Endocrinology, Diabetes & Metabolism Case ReportsDrug-induced pancreatitis represents 1.1% of acute pancreatitis cases. To date, eight cases of antithyroid drug (ATD)-induced pancreatitis have been reported, including seven associated with methimazole (MMI) and one with carbimazole; however, no cases ...
Yuriko Yamazaki +8 more
doaj +2 more sources
Hepatoprotective Effect of Acetylated Amino Acid on Methimazole Induced Hepatotoxicity in Mice
Journal of Islamic International Medical College, 2016 Objective: To explore the hepatoprotective effect of N‐acetylcysteine on methimazole induced hepatic damage in mice. Study Design: Randomized control trial.
Zunera Hakim , Akbar Waheed , Aroosa Ishtiaq , Wardha Mazhar
doaj +1 more source
How to discontinue potassium iodide in combined therapy with methimazole for initial treatment of Graves’ disease [PDF]
Endocrine JournalThe combination of methimazole (MMI) and potassium iodide (KI) is often used to improve the thyroid function more quickly in the initial medical treatment of Graves’ disease when the levels of free T4 are ≥5.0 ng/dL.
Tsukasa Murakami +4 more
doaj +2 more sources
Infection-Associated Transient Neutropenia Mimicking Methimazole-Induced Agranulocytosis in Graves' Disease: A Diagnostic Dilemma. [PDF]
CureusSaiprasad S +3 more
europepmc +3 more sources
Effects of Enzyme Induction and/or Glutathione Depletion on Methimazole Induced Hepatotoxicity in Mice and the Protective Role of N-Acetylcysteine [PDF]
Advanced Pharmaceutical Bulletin, 2014 Purpose: Methimazole is the most convenient drug used in the management of hyperthyroid patients. However, associated with its clinical use is hepatotoxicity as a life threatening adverse effect.
Reza Heidari +3 more
doaj +1 more source
The Role of Endoplasmic Reticulum Stress in Cell Injury Induced by Methimazole on Pancreatic Cells [PDF]
Advanced Pharmaceutical Bulletin, 2023 Purpose: Methimazole is an anti-thyroid agent, especially as main therapy option for Graves’ disease in children and adults. Drug induced pancreatitis is one of the known adverse effect of methimazole mentioned in case reports.
Özge Yazıcı +3 more
doaj +1 more source
Metabolite Changes during the Transition from Hyperthyroidism to Euthyroidism in Patients with Graves’ Disease [PDF]
Endocrinology and Metabolism, 2022 Background An excess of thyroid hormones in Graves’ disease (GD) has profound effects on systemic energy metabolism that are currently partially understood.
Ho Yeop Lee +9 more
doaj +1 more source
Cytoprotective Effects of Organosulfur Compounds against Methimazole-Induced Toxicity in Isolated Rat Hepatocytes [PDF]
Advanced Pharmaceutical Bulletin, 2013 Purpose: Methimazole is a drug widely used in hyperthyroidism. However, life-threatening hepatotoxicity has been associated with its clinical use. No protective agent has been found to be effective against methimazole-induced hepatotoxicity yet.
Mohammad Ali Eghba +2 more
doaj +1 more source